Aneurysmal Subarachnoid Hemorrhage (aSAH) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035

Aneurysmal Subarachnoid Hemorrhage (aSAH) Market Outlook

Thelansis's "Aneurysmal Subarachnoid Hemorrhage (aSAH) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Aneurysmal Subarachnoid Hemorrhage treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Aneurysmal Subarachnoid Hemorrhage (aSAH) Overview

Aneurysmal Subarachnoid Hemorrhage is a life-threatening emergency caused by intracranial aneurysm rupture, releasing arterial blood into the subarachnoid space and triggering acute intracranial hypertension. Thunderclap headache, meningism, photophobia, and impaired consciousness are hallmark features. Non-contrast CT confirms diagnosis; lumbar puncture detects xanthochromia when CT is negative. Hunt-Hess and WFNS grading reflect severity. Surgical clipping or endovascular coiling secures the aneurysm. Oral nimodipine prevents delayed cerebral ischemia, a multifactorial process distinct from angiographic vasospasm. TCD surveillance monitors flow velocities; refractory ischemia warrants induced hypertension and endovascular rescue. Survivors require rehabilitation and neuropsychological support.

Key Highlights

• In Germany, the diagnosed aSAH population is projected to increase from approximately 5,883 in 2025 to 6,278 by 2035.
• aSAH remains a life-threatening neurological emergency associated with high mortality and long-term disability.
• Early aneurysm detection and rapid intervention remain essential to improving clinical outcomes.
• Delayed cerebral ischemia and vasospasm continue to represent major post-hemorrhage complications.
• Advances in neurocritical care and endovascular techniques are improving patient survival.

Market Overview

• The France aSAH market is projected to grow from approximately $60 MN to $130 MN by 2035.
• Market growth is supported by:
• Increasing utilization of advanced neurointerventional procedures
• Improved acute care and long-term neurological management
• Market value growth is driven by high treatment intensity and hospitalization costs.
• Future growth will depend on innovative neuroprotective therapies and improved critical care strategies.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country